The News Caravan

Tag: intranasal

  • 3 lakh doses of intranasal Covid vaccine sent to hospitals: Bharat Biotech’s Krishna Ella

    3 lakh doses of intranasal Covid vaccine sent to hospitals: Bharat Biotech’s Krishna Ella

    [ad_1]

    New Delhi: Bharat Biotech dispatched three lakh doses of its intranasal COVID-19 vaccine to some hospitals two days ago, the company’s executive chairman Krishna Ella said on Sunday.

    He was speaking on the sidelines of an event here at which a bilateral agreement was signed between the University of Wisconsin (UW)-Madison Global Health Institute (GHI) and the Ella Foundation for the establishment of the first-ever UW-Madison One Health Centre in Bengaluru.

    iNCOVACC, the world’s first intranasal COVID-19 vaccine, was launched on January 26. The vaccine is now available on CoWIN and priced at Rs 800 for private markets and Rs 325 for the government of India and state governments.

    “We dispatched three lakh doses of the world’s first intranasal COVID-19 vaccine to some hospitals two days ago,” Ella said.

    On whether Bharat Biotech is looking at exporting the vaccine, he said some countries and international agencies are approaching the company for the intra-nasal vaccine.

    Innova is also the world’s first intranasal COVID-19 vaccine to receive approval for the primary 2-dose schedule, and as a heterologous booster dose for adults.

    Ella said the UW-Madison One Health Centre in Bengaluru is expected to be operational by the end of 2023.

    It will advance the development and production of new vaccines for India. Furthermore, the partnership will enable collaboration across disciplines and geographic boundaries, provide Indian students and researchers access to UW expertise and training, and build research capacity in India, he said.

    “Both Ella Foundation and UW-Madison GHI share a common vision to advance innovation in science, research, and knowledge sharing. Establishing the UW-Madison Global One Health Centre holds great significance as it will advance global health through research, education, and community engagement by facilitating student, and faculty exchanges, research and education,” he added.

    UW-Madison GHI director Jorge Osorio said, “We are energised by the opportunity to partner with the Ella Foundation to bring UW knowledge and expertise to expand innovative and impactful health initiatives outside Wisconsin to India.”

    The India One Health Centre joins a global network that includes Africa and Latin America and will open new opportunities for research, education, and provide actionable outcomes to benefit humans, animals, and ecosystems that advance equitable and sustainable health across India and the world.

    [ad_2]
    #lakh #doses #intranasal #Covid #vaccine #hospitals #Bharat #Biotechs #Krishna #Ella

    ( With inputs from www.siasat.com )

  • India’s first intranasal COVID-19 vaccine iNNCOVACC launched

    India’s first intranasal COVID-19 vaccine iNNCOVACC launched

    [ad_1]

    New Delhi: Union Health Minister Mansukh Mandaviya on Thursday unveiled the COVID-19 vaccine, iNNCOVACC in the presence of Union Minister of State (IC) for Science and Technology, Jitendra Singh.

    iNNCOVACC is the world’s first intranasal Covid-19 vaccine to receive approval for the primary 2-dose schedule, and as a heterologous booster dose. It is developed by Bharat Biotech International Limited (BBIL) in collaboration with Biotechnology Industry Research Assistance Council (BIRAC), a PSU under the Department of Biotechnology, Ministry of Science and Technology.

    Expressing his elation at the event, Mandaviya said that over 65 per cent of vaccines supplied in the world are from India.

    Congratulating the BBIL team and the Department of Biotech for bringing about the world’s first nasal vaccine, he stated that “being the world’s first intra-nasal Covid-19 vaccine, this marks a glorious tribute to the call for Atmanirbhar Bharat.”

    The Union Health Minister added that India’s vaccine manufacturing and innovation capability is appreciated all over the world as it has made a mark in producing quality and affordable medicines.

    Congratulating BBIL for innovating another vaccine in collaboration with BIRAC, Jitendra Singh said that “India has taken a lead in developing vaccines and medicines for diseases common in the developing world.”

    He also stated that ZyCoV-D, the world’s first and India’s indigenously developed DNA based vaccine for Covid-19 to be administered in humans including children and adults 12 years and above, was also developed in partnership with the Department of Biotechnology in the Ministry of Science & Technology under ‘Mission Covid Suraksha’ through BIRAC.

    iNCOVACC is a cost effective Covid-19 vaccine which does not require syringes, needles, alcohol wipes, bandage, etc, saving costs related to procurement, distribution, storage, and biomedical waste disposal, that is routinely required for injectable vaccines.

    It utilises a vector-based platform, which can be easily updated with emerging variants leading to large scale production, within a few months. These rapid response timelines combined with the ability of cost effective and easy intranasal delivery, makes it an ideal vaccine to address future infectious diseases.

    A rollout of iNCOVACC is expected to begin in private hospitals that have placed advance orders. Initial manufacturing capacity of several million doses per annum has been established, this can be scaled up to a billion doses as required. iNCOVACC is priced at Rs 325 per dose for large volume procurement by State Governments and Government of India.

    –

    [ad_2]
    #Indias #intranasal #COVID19 #vaccine #iNNCOVACC #launched

    ( With inputs from www.siasat.com )